{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T05:49:41Z","timestamp":1792388981512,"version":"4.4.0"},"reference-count":148,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["T32 DK074367"],"award-info":[{"award-number":["T32 DK074367"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bbamcr.2021.119047","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T04:40:22Z","timestamp":1619844022000},"page":"119047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Targeting epigenetic mechanisms to overcome venetoclax resistance"],"prefix":"10.1016","volume":"1868","author":[{"given":"Gabriel","family":"Prado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.","family":"Kaestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0005","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0092-8674(85)80070-2","article-title":"Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18","volume":"41","author":"Bakhshi","year":"1985","journal-title":"Cell"},{"issue":"4678","key":"10.1016\/j.bbamcr.2021.119047_bb0010","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.cr.7310028","article-title":"How the Bcl-2 family of proteins interact to regulate apoptosis","volume":"16","author":"van Delft","year":"2006","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0020","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/1078155219895079","article-title":"Driving toward precision medicine for B cell lymphomas: targeting the molecular pathogenesis at the gene level","volume":"26","author":"Chung","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2016-12-759621","article-title":"BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation","volume":"130","author":"Tsuyama","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","article-title":"bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation","volume":"57","author":"McDonnell","year":"1989","journal-title":"Cell"},{"issue":"28","key":"10.1016\/j.bbamcr.2021.119047_bb0035","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"39","key":"10.1016\/j.bbamcr.2021.119047_bb0040","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","article-title":"BCL-2 family isoforms in apoptosis and cancer","volume":"10","author":"Warren","year":"2019","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"269","key":"10.1016\/j.bbamcr.2021.119047_bb0055","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119047_bb0060","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1158\/0008-5472.CAN-03-3970","article-title":"Microarray analysis of epigenetic silencing of gene expression in the KAS-6\/1 multiple myeloma cell line","volume":"64","author":"Pompeia","year":"2004","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119047_bb0065","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3109\/10428194.2012.661854","article-title":"Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed\/refractory disease with therapeutic implications","volume":"53","author":"Hatzimichael","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119047_bb0070","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/carcin\/bgh145","article-title":"Inactivating mutations of proapoptotic Bad gene in human colon cancers","volume":"25","author":"Lee","year":"2004","journal-title":"Carcinogenesis"},{"issue":"16","key":"10.1016\/j.bbamcr.2021.119047_bb0075","doi-asserted-by":"crossref","first-page":"9324","DOI":"10.1073\/pnas.1533446100","article-title":"Bad-deficient mice develop diffuse large B cell lymphoma","volume":"100","author":"Ranger","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7042","key":"10.1016\/j.bbamcr.2021.119047_bb0080","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.bbamcr.2021.119047_bb0090","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1038\/sj.onc.1210028","article-title":"A novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma","volume":"26","author":"Chauhan","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.109.060780","article-title":"The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs","volume":"77","author":"High","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119047_bb0105","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.bbamcr.2021.119047_bb0115","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0125","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119047_bb0130","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.bbamcr.2021.119047_bb0135","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119047_bb0140","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0150","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"43","key":"10.1016\/j.bbamcr.2021.119047_bb0155","doi-asserted-by":"crossref","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119047_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0165","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119047_bb0175","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0180","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.18632\/oncotarget.2096","article-title":"Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia","volume":"6","author":"Yeh","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0185","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/leu.2011.287","article-title":"MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex","volume":"26","author":"Konopleva","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119047_bb0190","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1182\/blood-2007-04-083204","article-title":"MEK1\/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism","volume":"110","author":"Pei","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0195","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0200","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"issue":"5845","key":"10.1016\/j.bbamcr.2021.119047_bb0205","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1126\/science.1147939","article-title":"UHRF1 plays a role in maintaining DNA methylation in mammalian cells","volume":"317","author":"Bostick","year":"2007","journal-title":"Science"},{"issue":"5929","key":"10.1016\/j.bbamcr.2021.119047_bb0210","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119047_bb0215","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119047_bb0220","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","article-title":"The diverse roles of DNA methylation in mammalian development and disease","volume":"20","author":"Greenberg","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119047_bb0225","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0235","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","article-title":"The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers","volume":"25","author":"Russler-Germain","year":"2014","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.bbamcr.2021.119047_bb0240","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1073\/pnas.81.22.6993","article-title":"Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine","volume":"81","author":"Santi","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119047_bb0245","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1128\/MCB.25.11.4727-4741.2005","article-title":"5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal","volume":"25","author":"Ghoshal","year":"2005","journal-title":"Mol. Cell. Biol."},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119047_bb0250","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119047_bb0255","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0260","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V64.4.922.922","article-title":"5-Aza-2\u2032-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias","volume":"64","author":"Pinto","year":"1984","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bbamcr.2021.119047_bb0265","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1182\/blood-2009-01-200519","article-title":"MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation","volume":"114","author":"Figueroa","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0270","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0275","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.bbamcr.2021.119047_bb0280","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1038\/sj.onc.1211018","article-title":"p21(WAF1\/CIP1) induction by 5-azacytosine nucleosides requires DNA damage","volume":"27","author":"Jiemjit","year":"2008","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.bbamcr.2021.119047_bb0285","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann. Hematol."},{"issue":"13","key":"10.1016\/j.bbamcr.2021.119047_bb0290","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","author":"Jin","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0295","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine versus intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"Maiti","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119047_bb0300","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-Day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0305","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0310","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bbamcr.2021.119047_bb0315","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/leu.2010.113","article-title":"IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0320","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"7390","key":"10.1016\/j.bbamcr.2021.119047_bb0325","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbamcr.2021.119047_bb0330","doi-asserted-by":"crossref","first-page":"12700","DOI":"10.1038\/ncomms12700","article-title":"The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway","volume":"7","author":"Carbonneau","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0335","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0340","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"23","key":"10.1016\/j.bbamcr.2021.119047_bb0345","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.V126.23.323.323","article-title":"Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1\/2 trial","volume":"126","author":"Stein","year":"2015","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.bbamcr.2021.119047_bb0350","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2020.38.15_suppl.7500","article-title":"Phase Ib\/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +\/\u2212 azacitidine in IDH1-mutated hematologic malignancies","volume":"38","author":"Lachowiez","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbamcr.2021.119047_bb0355","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/blood-2018-99-119688","article-title":"Combination of enasidenib and venetoclax shows superior anti-leukemic activity against IDH2 mutated AML in patient-derived xenograft models","volume":"132","author":"Cathleen","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0360","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI133344","article-title":"Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2","volume":"130","author":"Dutta","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbamcr.2021.119047_bb0365","series-title":"Epigenetics","first-page":"984","author":"Allis","year":"2015"},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119047_bb0370","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbamcr.2021.119047_bb0375","series-title":"1 volume (various pagings)","article-title":"Molecular biology of the cell","author":"Alberts","year":"2015"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0380","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg3607","article-title":"Chromatin modifiers and remodellers: regulators of cellular differentiation","volume":"15","author":"Chen","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0385","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41576-018-0089-8","article-title":"Chromatin accessibility and the regulatory epigenome","volume":"20","author":"Klemm","year":"2019","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0390","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/embo-reports\/kvf053","article-title":"Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics","volume":"3","author":"Eberharter","year":"2002","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0395","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0400","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119047_bb0405","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic determinants of cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119047_bb0410","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/0008-5472.CAN-08-3907","article-title":"Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome","volume":"69","author":"Elsheikh","year":"2009","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0415","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1531","article-title":"Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer","volume":"37","author":"Fraga","year":"2005","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119047_bb0420","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2009.24.5639","article-title":"Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704","volume":"28","author":"Manuyakorn","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7046","key":"10.1016\/j.bbamcr.2021.119047_bb0425","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nature03672","article-title":"Global histone modification patterns predict risk of prostate cancer recurrence","volume":"435","author":"Seligson","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0430","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2353\/ajpath.2009.080874","article-title":"Global levels of histone modifications predict prognosis in different cancers","volume":"174","author":"Seligson","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.bbamcr.2021.119047_bb0435","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng.3525","article-title":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","volume":"48","author":"Bonilla","year":"2016","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.bbamcr.2021.119047_bb0440","first-page":"1565","article-title":"p300 gene alterations in colorectal and gastric carcinomas","volume":"12","author":"Muraoka","year":"1996","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0445","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/73536","article-title":"Mutations truncating the EP300 acetylase in human cancers","volume":"24","author":"Gayther","year":"2000","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.bbamcr.2021.119047_bb0450","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.yexcr.2012.01.025","article-title":"HDAC modulation and cell death in the clinic","volume":"318","author":"Dell\u2019Aversana","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC inhibitor: from cancer to cardiovascular diseases","volume":"52","author":"Yoon","year":"2016","journal-title":"Chonnam Med. J."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0460","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/cancers7010030","article-title":"p53 acetylation: regulation and consequences","volume":"7","author":"Reed","year":"2014","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0465","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.lungcan.2011.02.019","article-title":"Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung","volume":"74","author":"Minamiya","year":"2011","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119047_bb0470","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-08-2319","article-title":"Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression","volume":"15","author":"Suzuki","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0475","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/auto.22399","article-title":"BCL2L11\/BIM: a novel molecular link between autophagy and apoptosis","volume":"9","author":"Luo","year":"2013","journal-title":"Autophagy"},{"issue":"17","key":"10.1016\/j.bbamcr.2021.119047_bb0480","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119047_bb0485","first-page":"3893","article-title":"Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo","volume":"8","author":"Schwartz","year":"2016","journal-title":"Am. J. Transl. Res."},{"issue":"19","key":"10.1016\/j.bbamcr.2021.119047_bb0490","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2021.119047_bb0495","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood-2018-99-117403","article-title":"Combined BCL-2 and HDAC targeting has potent and TP53 independent activity in AML","volume":"132","author":"Salmon","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0500","first-page":"1262","article-title":"The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia","volume":"106","author":"Li","year":"2021","journal-title":"Haematologica"},{"issue":"33","key":"10.1016\/j.bbamcr.2021.119047_bb0505","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7330","key":"10.1016\/j.bbamcr.2021.119047_bb0510","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119047_bb0515","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.stem.2014.05.006","article-title":"Chromatin repressive complexes in stem cells, development, and cancer","volume":"14","author":"Laugesen","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"5595","key":"10.1016\/j.bbamcr.2021.119047_bb0520","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1076997","article-title":"Role of histone H3 lysine 27 methylation in Polycomb-group silencing","volume":"298","author":"Cao","year":"2002","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0525","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0092-8674(02)00975-3","article-title":"Drosophila enhancer of Zeste\/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites","volume":"111","author":"Czermin","year":"2002","journal-title":"Cell"},{"issue":"47","key":"10.1016\/j.bbamcr.2021.119047_bb0530","doi-asserted-by":"crossref","first-page":"18439","DOI":"10.1073\/pnas.0707292104","article-title":"Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases","volume":"104","author":"Hong","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"14","key":"10.1016\/j.bbamcr.2021.119047_bb0535","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0540","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ng.349","article-title":"Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer","volume":"41","author":"van Haaften","year":"2009","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0545","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0550","first-page":"25","article-title":"EZH2 overexpression as a useful prognostic marker for aggressive behaviour in thyroid cancer","volume":"32","author":"Masudo","year":"2018","journal-title":"In Vivo"},{"issue":"12","key":"10.1016\/j.bbamcr.2021.119047_bb0555","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123707","article-title":"Aberrant epigenetic regulation in head and neck cancer due to distinct EZH2 overexpression and DNA hypermethylation","volume":"19","author":"Mochizuki","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0560","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.27","article-title":"Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control","volume":"7","author":"Pawlyn","year":"2017","journal-title":"Blood Cancer J."},{"issue":"24 Pt 1","key":"10.1016\/j.bbamcr.2021.119047_bb0565","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1158\/1078-0432.CCR-05-1047","article-title":"Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder","volume":"11","author":"Raman","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0570","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/15384047.2019.1672455","article-title":"Clinical and biological significance of EZH2 expression in endometrial cancer","volume":"21","author":"Roh","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"6907","key":"10.1016\/j.bbamcr.2021.119047_bb0575","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bbamcr.2021.119047_bb0580","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.biopha.2015.07.038","article-title":"Clinical and prognostic relevance of EZH2 in breast cancer: a meta-analysis","volume":"75","author":"Wang","year":"2015","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119047_bb0585","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/1389203716666150409100233","article-title":"Targeting EZH2 for cancer therapy: progress and perspective","volume":"16","author":"Han Li","year":"2015","journal-title":"Curr. Protein Pept. Sci."},{"issue":"20","key":"10.1016\/j.bbamcr.2021.119047_bb0590","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1093\/emboj\/cdg542","article-title":"EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer","volume":"22","author":"Bracken","year":"2003","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0595","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0600","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neo.2016.01.003","article-title":"Somatic copy number amplification and hyperactivating somatic mutations of EZH2 correlate with DNA methylation and drive epigenetic silencing of genes involved in tumor suppression and immune responses in melanoma","volume":"18","author":"Tiffen","year":"2016","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119047_bb0605","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2021.119047_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2019.103614","article-title":"Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines","volume":"213","author":"Hao","year":"2020","journal-title":"J. Proteome"},{"issue":"12","key":"10.1016\/j.bbamcr.2021.119047_bb0615","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.jid.2020.02.042","article-title":"EZH2 cooperates with DNA methylation to downregulate key tumor suppressors and IFN gene signatures in melanoma","volume":"140","author":"Tiffen","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"19","key":"10.1016\/j.bbamcr.2021.119047_bb0620","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.febslet.2012.07.066","article-title":"A687V EZH2 is a gain-of-function mutation found in lymphoma patients","volume":"586","author":"Majer","year":"2012","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.bbamcr.2021.119047_bb0625","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1073\/pnas.1116418109","article-title":"Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)","volume":"109","author":"McCabe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.bbamcr.2021.119047_bb0630","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1158\/1078-0432.CCR-13-2499","article-title":"Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination","volume":"20","author":"Ezponda","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0635","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"15","key":"10.1016\/j.bbamcr.2021.119047_bb0640","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0645","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"Beguelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.bbamcr.2021.119047_bb0650","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1182\/bloodadvances.2020002580","article-title":"Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes","volume":"4","author":"Scholze","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0655","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/cdd.2009.162","article-title":"Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression","volume":"17","author":"Wu","year":"2010","journal-title":"Cell Death Differ."},{"issue":"12","key":"10.1016\/j.bbamcr.2021.119047_bb0660","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nrm2298","article-title":"Multivalent engagement of chromatin modifications by linked binding modules","volume":"8","author":"Ruthenburg","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bbamcr.2021.119047_bb0665","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/MCB.01020-07","article-title":"Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression","volume":"28","author":"Yang","year":"2008","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119047_bb0670","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.bbamcr.2021.119047_bb0675","doi-asserted-by":"crossref","first-page":"E5086","DOI":"10.1073\/pnas.1712363115","article-title":"Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma","volume":"115","author":"Xu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7370","key":"10.1016\/j.bbamcr.2021.119047_bb0680","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0685","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.1422165112","article-title":"An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma","volume":"112","author":"Baratta","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6241","key":"10.1016\/j.bbamcr.2021.119047_bb0690","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbamcr.2021.119047_bb0695","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"issue":"49","key":"10.1016\/j.bbamcr.2021.119047_bb0700","doi-asserted-by":"crossref","first-page":"29193","DOI":"10.18632\/oncotarget.25670","article-title":"BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition","volume":"9","author":"Kim","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bbamcr.2021.119047_bb0705","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-15-0924","article-title":"BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members","volume":"15","author":"Hogg","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.bbamcr.2021.119047_bb0710","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/leu.2017.10","article-title":"Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia","volume":"31","author":"Peirs","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0715","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/jcmm.14857","article-title":"Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia","volume":"24","author":"Carra","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"14","key":"10.1016\/j.bbamcr.2021.119047_bb0720","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1038\/s41388-017-0111-1","article-title":"The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1\/A1 in in vitro and in vivo models of MYC+\/BCL2+ double hit lymphoma","volume":"37","author":"Esteve-Arenys","year":"2018","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bbamcr.2021.119047_bb0725","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-018-0165-5","article-title":"Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells","volume":"9","author":"Fiskus","year":"2019","journal-title":"Blood Cancer J."},{"issue":"14","key":"10.1016\/j.bbamcr.2021.119047_bb0730","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/bloodadvances.2020002231","article-title":"BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression","volume":"4","author":"Cummin","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.bbamcr.2021.119047_bb0735","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbamcr.2021.119047_bb0740","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488921001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488921001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T19:56:49Z","timestamp":1759089409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488921001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":148,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0167488921001014"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2021.119047","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting epigenetic mechanisms to overcome venetoclax resistance","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2021.119047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119047"}}